Editas Medicine (EDIT) Return on Capital Employed (2016 - 2025)
Editas Medicine (EDIT) reported Return on Capital Employed of 137.71% for Q3 2025, down 5720.0% year-over-year from 2.45% in Q3 2024, and up 1.76% on a QoQ basis from 140.18% in Q2 2025.
Editas Medicine (EDIT) has 10 years of Return on Capital Employed data on file, last reported at 137.71% in Q3 2025.
- Quarterly Return on Capital Employed fell 5720.0% year-over-year to 137.71% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 137.71% (down 5720.0% YoY) and the FY2024 annual result came in at 73.19%, down 3505.0% from the prior year.
- Return on Capital Employed climbed to 137.71% in Q3 2025 per EDIT's latest filing, from 140.18% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 23.69% in Q1 2021 and bottomed at 140.18% in Q2 2025.
- The 5-year median for Return on Capital Employed is 45.93% (2024), against an average of 59.13%.
- The widest annual swing landed in 2021, when Return on Capital Employed jumped 1361 bps; it then sank 7721 bps in 2025.
- Tracing EDIT's Return on Capital Employed over 5 years: stood at 29.7% in 2021, then plunged by 64 bps to 48.85% in 2022, then increased by 21 bps to 38.57% in 2023, then sank by 153 bps to 97.59% in 2024, then plunged by 41 bps to 137.71% in 2025.
- Per Business Quant, the three latest EDIT Return on Capital Employed figures stand at 137.71% (Q3 2025), 140.18% (Q2 2025), and 113.43% (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -137.71% |
| Jun 30, 2025 | -140.18% |
| Mar 31, 2025 | -113.43% |
| Dec 31, 2024 | -97.59% |
| Sep 30, 2024 | -80.51% |
| Jun 30, 2024 | -62.97% |
| Mar 31, 2024 | -45.93% |
| Dec 31, 2023 | -38.57% |
| Sep 30, 2023 | -44.90% |
| Jun 30, 2023 | -48.16% |
| Mar 31, 2023 | -52.35% |
| Dec 31, 2022 | -48.85% |
| Sep 30, 2022 | -39.74% |
| Jun 30, 2022 | -32.86% |
| Mar 31, 2022 | -30.47% |
| Dec 31, 2021 | -29.70% |
| Sep 30, 2021 | -31.71% |
| Jun 30, 2021 | -24.10% |
| Mar 31, 2021 | -23.69% |
| Dec 31, 2020 | -25.60% |
| Sep 30, 2020 | -18.97% |
| Jun 30, 2020 | -30.83% |
| Mar 31, 2020 | -37.30% |
| Dec 31, 2019 | -37.02% |
| Sep 30, 2019 | -42.98% |
| Jun 30, 2019 | -37.17% |
| Mar 31, 2019 | -31.63% |
| Dec 31, 2018 | -30.90% |
| Sep 30, 2018 | -31.34% |
| Jun 30, 2018 | -33.11% |
| Mar 31, 2018 | -32.17% |
| Sep 30, 2017 | -37.74% |
| Jun 30, 2017 | -35.08% |
| Mar 31, 2017 | -42.00% |
| Dec 31, 2016 | -47.97% |
| Sep 30, 2016 | -30.41% |
| Jun 30, 2016 | -24.12% |
| Mar 31, 2016 | -25.41% |